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ABSTRACT
Inhibition of miR26a microRNA restores sensitivity to temozolomide
by Angela Grace Stewart
MicroRNAs have been associated with tumorgenesis of Glioblastoma Multiforme
(GBM). A microRNA (miRNA) is a small RNA (22-25 nucleotides) that can prevent
the translation of messenger RNA (mRNA) into protein by binding the mRNA
(Huse et al. 2008, Zamore and Haley 2005). The miRNA/mRNA complex is then
degraded. PTEN is a tumor suppressor protein which regulates the AKT/PIP3
pathway, which is active in many cellular regulatory pathways. The microRNA miR-26a
is known to bind PTEN mRNA. The loss of PTEN promotes ideal conditions for the
unregulated growth of tumor cells and Huse et al. (2008) demonstrated that miR-26a is
frequently amplified in human glioma. Jiang and colleagues (2007) reported that the
lack of PTEN influences the cells ability to resist chemotherapy treatment, specifically
temozolomide (TMZ). TMZ is the current chemotherapy standard of care for GBM
patients. This study investigated a possible link between miR-26a inhibition and TMZ
sensitivity. LN229 glioma cell line (wild-type PTEN and miR-26a positive) was treated
with a miR26a oligo inhibitor, and subsequent TMZ treatment. Cellular proliferation
was assayed. We demonstrated that treatment of LN229 glioma cells with the
combination of microRNA inhibitor and TMZ resulted in a marked decrease in cell
proliferation and viability.
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INTRODUCTION

Glioblastoma multiforme (GBM) is one of the most common and aggressive
types of brain tumors (Huse et al. 2008). The World Health Organization (WHO)
classifies GBM as a grade IV tumor due to its poor prognosis and median
survival of 14 months after diagnosis. GBMs are heterogeneous; a single tumor
may have a variety of cell types with distinct alterations to specific signal
transduction pathways.

GBM requires aggressive treatment including surgery,

chemotherapy and radiation, however there has been little advancement in GBM
treatments since the introduction of temozolomide as a treatment option.
Inactivation of PTEN has been shown to be involved in the formation of
heritable and sporadic cancers (Planchon 2007). It has been demonstrated that
the AKT signaling pathway can be continuously activated in GBMs, and in some
cases this activation is due, in part, to the loss of Phosphatase and Tensin
Homolog (PTEN) expression. PTEN contains both a protein phosphatase and a
tensin-like region involved in cell adhesion and is a negative regulator of the AKT
pathway. AKT is a serine/threonine protein kinase with several important roles
in multiple cellular processes including; cell proliferation, cell survival,
transcription and cell migration (Wang 2012). Phosphatidylinositol 3, 4, 5 triphosphate (PIP3), is a signaling molecule that activates AKT, setting in motion a
cascade of signaling pathways. PTEN negatively regulates the AKT signaling
1

pathway by dephosphorylating PIP3 to phosphatidylinositol 4, 5 bi-phosphate
(PIP2) and PIP2 cannot activate AKT thus preventing unregulated cell growth.
With the loss of PTEN, PIP3 can accumulate within the cell creating a consistent
stream of activation for AKT.
Additionally a recent review paper by Parsa et al. (2007) showed a connection
between the loss of PTEN and an increase in B7-H1 cell surface receptors on
GBM cells. B7 is traditionally a receptor on antigen presenting cells, that when
paired with the CD28 receptor of T cells causes a stimulatory signal to illicit an
immune response. B7-H1 (B7 homolog) which is up regulated with the loss of
PTEN assists the tumor cells in evading the immune system. The signal produced
when T cells interact with B7-H1 is inhibitory and prevents a response. PTEN
deficient cells were thus rendered less susceptible to cytotoxic T lymphocytemediated targeting (Waziri et al. 2010). Tumor specific T cells were found to lyse
human glioma targets expressing wild-type PTEN more effectively than those
expressing mutant PTEN; this data identifies an unrecognized mechanism linking
loss of the tumor suppressor PTEN with immunoresistance (Parsa et al. 2007).
Treatment of patients with drugs that selectively target cancer cells with loss of
PTEN could improve response to T cell mediated immunotherapy by decreasing
local immunoresistance (Parsa et al. 2007). The results of Parsa et al. (2007)
could impact immunotherapy trials by defining the loss of PTEN function as
important molecular screening criteria.
2

Recent studies have shown that PTEN can be epigenetically silenced.
Epigenetics is a way of altering gene expression that does not involve changes in
the nucleotide sequence of DNA or RNA. Epigenetic regulation is manifested as
methyl groups added to DNA/RNA following replication or miRNA binding to
mRNA preventing translation. Another epigenetic regulator of PTEN is miR-26a
microRNA.
MicroRNAs (miRNAs) are small (~22 nucleotides), post-transcriptional
regulators that bind to complementary sequences in the three prime untranslated
regions (3’ UTR) of target messenger RNA transcripts (mRNAs), usually
resulting in gene silencing (Huse et al. 2008). MiRNAs are small noncoding RNA
molecules that regulate protein expression by targeting the mRNA of protein
coding genes for either cleavage or repression of translation (Chan et al. 2005).
The miRNA works to sequester the mRNA by binding to it and preventing
translation. Most miRNA genes are found in intergenic regions (between gene
clusters) making it an endogenous molecule. The miRNA genes contain their
own promoter and regulatory units. MiR-26a in particular acts on the mRNA of
PTEN, acting as a miRNA associated with cancer or oncomiR that negatively
regulates PTEN protein. Huse et al. (2008) demonstrated that miR-26a is
frequently amplified in human glioma, and miR-26a-mediated PTEN repression
in a murine glioma model enhances de novo tumor formation. The biogenesis of
miRNA requires several posttranscriptional steps to yield the functional mature
3

miRNA (Esquela-Kerscher and Slack 2006). MiRNAs are created by the
microprocessor complex of Drosha and DGCR8 (Esquela-Kerscher and Slack
2006). Drosha is in the RNAse-III family and is activated when bound to the
nuclear protein DGCR8 (which is also known as pasha).This complex cleaves the
correct 70 nucleotides from the miRNA gene creating the primary miRNA (primiRNA). The pri-miRNA is then cleaved into a double stranded stem and loop
conformation with a 2 nucleotide overhang, resulting in what is known as the
preliminary miRNA (pre-miRNA). The pre-miRNA is exported out of the
nucleus by exportin-5, which recognizes the 2 nucleotide overhang, and RanGTP. Ran-GTP or Ras associated nuclear protein transports molecules in/out of
the nucleus. This action of transport is dependent on the hydrolysis of guanine
triphosphate (GTP) to guanine diphosphate (GDP). Once in the cytoplasm the
pre-miRNA complex binds to Dicer. Dicer is an endoribonuclease that cleaves
the pre-miRNA duplex. The now single strands of miRNA are considered
mature. When the mature miRNA is combined with the RNA-induced silencing
complex (RISC) the miRISC is formed (Esquela-Kerscher 2006). The miRISC is
the machinery that binds to mRNA transcripts allowing the miRNA to interact
with its target mRNA. Degradation of the target mRNA only occurs if there is
perfect complementary binding. Some miRNA-mRNA binding complexes are
not perfectly complementary; the result is steric hindrance of the translational
machinery preventing mRNA translation into a functional protein (Figure 1).
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PTEN is often referred to as a haploinsufficient gene (Salmena et al. 2008).
Following the loss of one allele the remaining allele is not sufficient to produce a
functional protein. Epigenetic alterations such as miR-26a binding to the mRNA
of PTEN, prevents the production of a functional protein without loss of the
PTEN gene.

It has also been demonstrated in a murine model that over

expression of the miRNA can functionally substitute for the loss of
heterozygosity at the PTEN locus, leading to the haploinsufficient state of the
gene (Huse et al. 2008). Even with an intact PTEN locus, the over expression of
miR-26a creates the same haploinsufficient state as if the locus were deleted or
mutated. The roles of miRNAs in lineage determination and proliferation as well
as the location of several miRNA genes at sites of translocation breakpoints or
deletions has led to the speculation that miRNAs could be important factors in
the development or maintenance of the neoplastic state (Chan et al. 2005). As of
yet, no microRNA has been definitively shown to either enhance or suppress the
process of glioma formation in vivo. However, it has been demonstrated that miR26a reduces PTEN levels by directly targeting the PTEN mRNA transcript, by
binding to one of three known binding sites (Huse et al. 2008). With the loss of a
tumor suppressor gene, such as PTEN, the cell might be more likely to undergo
transformation. Additionally if PTEN has a role in TMZ functionality its loss
would increase chemotherapy resistance.
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Jiang and colleagues (2007) reported that decreased PTEN expression plays a role
in the cell’s ability to resist chemotherapy treatment, specifically temozolomide.
They reported that inducing PTEN expression down regulated AKT activity and
enhanced cell sensitivity to TMZ. The exact mechanism for TMZ resistance due
to PTEN loss is unknown at this time however it is speculated that the level of
phosphorylated AKT might play a role. Temozolomide is the current standard of
care for GBM chemotherapy and acts as an alkylating agent that adds a methyl
group to the O6 or N7 position on guanine residues in the cell’s DNA. This
alteration to the DNA activates the cells mis-match repair system (MMR)
(Chamberlain and Mrugala 2008). Continued mis-match by the cell’s MMR
mechanism creates accumulations of double stranded breaks. Ultimately cell
proliferation is halted by either apoptosis or termination of cell division, due to
the accumulation of DNA damage. An intact mis-match repair mechanism is
required for TMZ induced cytotoxicity (Chamberlain and Mrugala 2008).
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PROJECT OBJECTIVES

The GBM cell line LN229 (ATCC#CRL-2611) is reported to contain the wildtype PTEN gene, but also expresses the miRNA miR-26a (Huse et al. 2008,
Furnari et al. 1997). The LN229 cell line was established from a female
glioblastoma patient in 1979 (ATCC). The presence of miR-26a has an effect on
PTEN’s tumor suppressor ability by preventing translation of the genetic
information into a protein (Huse et al. 2008). If the presence of PTEN in the cell
is thought to increase the potency of its tumor suppression ability, the
knockdown of miR-26a should increase the amount of PTEN protein and
increase the LN229 cells sensitivity to chemotherapy agents such as TMZ. This
research examined the hypothesis that silencing of miR-26a will allow PTEN to
be translated into protein increasing the cells sensitivity to TMZ, resulting in a
decrease in the cells viability. The following steps were used to support this
hypothesis: LN229 glioma cells were confirmed to contain miR-26a using RTPCR. The miRNA was silenced with the transfection of an anti-miR-26a
oligonucleotide producing a decrease in cell viability. Relative levels of PTEN
protein were examined using a western blot, before and after transfection with
anti-miR26a. Temozolomide was then combined with the anti-miR-26a treatment
to verify further decrease in cell viability.
7

Chapter 1
PTEN: a tumor suppressor
Structure and Function of PTEN
Phosphatase and Tensin homolog (PTEN) is a lipid phosphatase tumor
suppressor protein. A ubiquitous inhibitor of the AKT pathway by
dephosphorylation of PIP3, PTEN assists in regulation of the cell cycle to
prevent unregulated growth (Leslie and Downes 2004). A member of the protein
tyrosine phosphatase family, PTEN removes phosphates from phosphorylated
tyrosine residues on proteins. Removal of the phosphate in the 3 position on the
inositol ring of tyrosine prevents activation of the AKT pathway by termination
of PIP3 signaling (Wang et al. 2012). The AKT pathway is responsible for cellular
survival mechanisms: glucose metabolism, cellular proliferation, prevention of
apoptosis, and cell migration (Wang et al. 2012). PIP3 binds AKT activating the
protein; once activated AKT moves to the cytoplasm and nucleus allowing for
stimulation of several downstream targets involved in cellular functions (Wang et
al. 2012). The level of PIP3 is very low in resting cells that contain wild type
PTEN. Cells that lack PTEN have elevated levels of PIP3, even in the resting
state. (Sulis and Parsons 2003). Functional PTEN maintains the cell cycle within
normal operating parameters; however a loss of functional PTEN can allow
unregulated cellular growth with the potential to become cancerous.
8

Mechanisms for loss of PTEN in Glioblastoma
The PTEN gene, which encodes for the PTEN protein, is located on
chromosome 10 and in some glioblastoma cases the locus for the PTEN gene is
mutated or deleted. Even partial loss of the PTEN gene prevents protein
production due to a haploinsufficient state (Leslie and Downes 2004 Salmena et
al. 2008). Haploinsufficiency is when one locus is not suitable to produce
adequate amounts of functional protein. The loss of functional protein can result
from mechanisms other than gene deletion. Leslie and Downes (2004) noted that
54% of glioblastomas have a loss of expression of PTEN, meaning there could
be an intrinsic mechanism preventing protein production. Epigenetic alteration of
the PTEN mRNA transcript would alter the amount of protein expressed in the
cell. Epigenetics manifest as methyl groups added to DNA/RNA or miRNA
binding post-transcriptionally. MicroRNAs are post-transcriptional regulators that
prevent translation of mRNAs and ultimately protein production. PTEN has two
well-known microRNAs found in GBMs that bind and prevent its protein
production; miR-21 and miR26a (Leslie and Foti 2011). The latter miRNA is
known to have 3 binding sites on the PTEN mRNA transcript, making it a more
attractive target for therapy (Huse et al. 2008).
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Materials and Methods
Western Blot
LN229 cells were plated at a density of 5x104 cells/well in a 24-well plate. The
cells were then harvested 24 hours later to create a whole cell lysate. Sample lysis
buffer was placed in boiling water to warm. The sample lysis buffer was
composed of 20 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 1%
SDS with a pH of 7.3. One hundred to 150 microliters of sample lysis buffer was
administered to each of the 24 wells to lyse the cells. The lysate was pipetted to
mix, collected and pooled, resulting in 4 mL total volume. The LN229 lysate was
determined to contain 1.1 µg/µL of protein using a BCA protein assay (Bio-Rad).
The lysate sample was combined with Laemmli sample buffer and pipetted into a
Bio-Rad SDS-Page pre cast gel in 15 µL and 50 µL volumes. The gel was run in
1x tris/Glycine/SDS running buffer at a constant voltage (39 v) for 55 minutes.
The gel was then placed on a nitrocellulose sheet in a Bio-Rad transfer cassette.
The transfer cassette was placed in western transfer solution (Tris 48 mM,
Glycine 39 mM, SDS 0.04%, 200 mL methanol and 800 mL dH20) in the BIORAD Power Pack machine at constant amperage 0.10 A, 39 v and 4 w for 10
hours. After the transfer, the nitrocellulose paper was placed in a 3% nonfat milk
blocking buffer for 30 min. The primary antibody, mouse monoclonal antiPTEN (Calbiochem), was applied in a 1:200 dilution and incubated for 11 hours.
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The secondary antibody, goat anti-mouse labeled with horseradish peroxidase
(Thermo scientific), was applied in a 1:1000 dilution, for 1 hour. Between the
primary and secondary antibody applications the membrane was washed 3 times
for 15 min each in TBST (Table 1). Following final antibody incubation the
membrane was washed 3 more times in TBST prior to visualization.
Visualization
Protein was visualized using SuperSignal ELISA Pico Chemiluminescent
Substrate (Bio-Rad). A 1:1 ratio (undiluted) of the substrate was applied to the
nitrocellulose paper. The proteins were imaged immediately using Kodak 1D
image system (Figure 2).
Results/Discussion
PTEN was confirmed to be present within the LN229 cell line as indicated by
well-defined bands in the western blot (Figure 2). This result was expected as the
LN229 cell line was previously reported to be wild-type for the PTEN protein
(Furnari et al. 1997). PTEN expression was expected due to the intact wild-type
gene. However if miR-26a is present the amount of protein should be decreased
but not necessarily completely eliminated. A decrease in PTEN protein may be
sufficient to alter the tumor suppressor role of PTEN and to alter the cells
response to the chemotherapy agent TMZ.
11

Chapter 2
Temozolomide: Current Standard of Care
Action of Temozolomide
Temozolomide (chemical structure: 3, 4-dihydro-3-methyl-4-oxoimidaso [5, 1-d]1, 2, 3, 5-tetrazine-8-caboxamide) is the current standard of care for
chemotherapy treatment of GBM. The drug has been used since August of 1999
in the United States. TMZ is efficiently absorbed after oral administration, and
readily crosses the blood-brain barrier (Chamberlain and Mrugala 2008). The
therapeutic benefit of TMZ depends on its ability to alkylate/methylate DNA.
TMZ adds a methyl group to either the O6 or N7 position on guanine residues.
The presence of the methyl group on the O6 position of the guanine residues
causes mis-matching during DNA replication, the guanine is matched with a
thymidine as opposed to a cytosine (Chamberlain and Mrugala 2008). The mismatch triggers activation of the cell’s mis-match repair system (MMR). The
MMR system removes the incorrect base pair match and the replication is
resumed. However, the same mis-match occurs again, due to the ongoing
presence of the methyl group. This mis-match and the futile repair keep
occurring until numerous double-stranded DNA breaks accumulate in the cell. It
is the accumulation of these double-stranded DNA breaks that leads the cell to
apoptosis.
12

Loss of PTEN and chemotherapy resistance
In breast cancer, reduction of PTEN by antisense oligonucleotides conferred
trastuzumab resistance in vitro and in vivo. Patients with PTEN-deficient breast
cancers had significantly poorer responses to trastuzumab-based therapy than
those with normal PTEN (Nagata et al. 2004). It has been demonstrated that
loss of PTEN decreases cells sensitivity to chemotherapy treatments in several
types of cancer and chemotherapies. In GBM decreased PTEN levels reduced
cell sensitivity to TMZ and induction of PTEN expression was found to enhance
cell sensitivity to TMZ (Jiang et al. 2007). PTEN can sensitize glioma cells to
chemotherapy and also induce apoptosis (Wang et al. 2002). When PTEN is
present it can sensitize cells to TMZ, allowing TMZ to have a greater affect in
decreasing cell viability compared to cells where PTEN is not present. Jiang et al.
(2007) also found that by inducing PTEN, in PTEN-deficient cells, TMZ
sensitivity was restored through a decrease in AKT pathway activity. The
induction of wild-type PTEN in U251-wtPTEN cells led to a statistically
significant increase in sensitivity to a range of temozolomide doses from 10 to 50
µmol/L (Jiang et al. 2007). The exact mechanism for the increase of sensitivity to
TMZ when functional PTEN is present has yet to be elucidated. It has been
suggested that a deficiency in MMR coupled with the haploinsufficiency of
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PTEN can account for resistance to TMZ and tumor progression. It has been
shown that MMR deficiency can accelerate tumorgenesis in PTEN +/- mice
(Wang et al. 2002). Another cellular mechanism that confers resistance to TMZ
is the presence of O6-methylguanine-DNA methyltransferase (MGMT). As
stated, TMZ is an alkylating agent that acts on the O6 or N7 positions on guanine
residues in DNA. The DNA changes created by TMZ are a major carcinogenic
lesion. The cell has mechanisms to repair such lesions; one mechanism is the
enzyme MGMT. MGMT is a suicide repair protein that removes the cytotoxic
O6 guanine produced by the alkylator-based chemotherapy, thereby inducing
resistance (Chamberlain and Mrugala 2008). The repair protein is not regenerated
once the alkyl group is removed. It has been reported that LN229 cells do not
express MGMT (Davis 2008). The lack of MGMT expression in LN229 cells
rules out MGMT as a mechanism for resistance.

14

Chapter 3
MicroRNA: Small RNAs with big impact
Biogenesis, Structure and Function
MicroRNAs are endogenous small RNAs that bind the 3’ UTR of target mRNA
transcripts. The miRNA genes possess all the necessary machinery to produce a
functional mature miRNA. The biogenesis of miRNA begins with the RNAse-III
enzyme Drosha and its cofactor DGCR8 (Esquela-Kerscher and Slack 2006).
DGCR8 is also known as pasha; a protein localized to the nucleus. Pasha binds to
Drosha forming the microprocessor complex. Pasha is thought to stabilize the
pri-miRNA for binding by Drosha (Esquela-Kerscher and Slack 2006). The
Drosha and DGCR8 complex recognizes the pri-miRNA sequence and cleave
the strand into a 70 nucleotide dsRNA with a 2 nucleotide overhang (Zamore
and Haley 2005). Once cleaved the pri-miRNA has a stem-loop conformation
with an overhang, this is now known as the pre-miRNA (Turner et al. 2010). The
pre-miRNA overhang is recognized by exportin-5 and Ran-GTPase which
exports the pre-miRNA, from the nucleus. Exportin-5 mediates transport of
cargo from the nucleus into the cytoplasm by interacting with Ran. Ran-GTPase
transports molecules in/out of the nucleus during interphase of mitosis. This
action of transport is GTP dependent, meaning the energy from the hydrolysis of
GTP to GDP is necessary. Once in the cytoplasm the pre-miRNA is further
15

digested by Dicer (Turner et al. 2010). Dicer is an endoribonuclease in the RNase
III family that cleaves the pre-miRNA into short double-stranded RNA
fragments. Cleavage by Dicer creates a mature miRNA (Turner et al. 2010). Dicer
then catalyzes the first step in the miRNA mediated interference of protein
expression. Formation of the RNA-induced silencing complex (RISC) allows the
mature miRNA to bind the target mRNA. RISC is also known as a microRNA
ribonucleoprotein complex (miRNP) and RISC with incorporated miRNA is
sometimes referred to as “miRISC” (Zamore and Haley 2005). The miRNP
RISC can either perfectly match the target mRNA transcript resulting in
degradation of the whole complex or bind and prevent translation due to steric
hindrance if not completely complementary (Esquela-Kerscher and Slack 2006;
Figure 1).
Materials and Methods
Cell Culture
The glioblastoma cell line LN229 (ATCC#CRL-2611) was used. LN229s were
cultured in Dulbecco’s modified Eagle’s medium (DMEM), 5% FBS. The cell
line was maintained without antibiotics, at 37°C in a humidified atmosphere
containing 5% CO2.
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Determination of miR-26a presence in LN229 cell line was accomplished by
SYBR Green miScript Reverse Transcription PCR.
Reverse Transcription
RNA Isolation/Purification
RNeasy Mini Kit (Qiagen) was used to isolate and purify total RNA, including
miRNA from the LN229 glioma cells following the manufacturer’s protocol.
Briefly, cells were grown in a culture flask as a monolayer until 90% confluent.
The cells were treated with trypsin-EDTA and pelleted prior to lysis. Cells were
disrupted by adding 600 µL of Buffer RLT to the pellet and then vortexed. The
lysate was pipetted directly into a QIAshredder spin column placed in a 2 mL
collection tube, centrifuged for 2 minutes at >8000 x g. One volume (600 µL) of
70% ethanol was added to the homogenized lysate, and mixed by pipetting. Up to
700 µL of the sample was transferred to an RNeasy spin column in a 2 mL
collection tube. The lid was closed securely and centrifuged for 15 seconds (s) at
>8000 x g. The flow through was discarded. Buffer RW1 (700 µL) was added to
the RNeasy spin column. The sample was centrifuged again for 15 s at >8000 x g.
Buffer RPE (500 µL) was added to the RNeasy spin column and centrifuged for
15 s at > 8000 x g, the flow through was again discarded. An additional 2 minute
centrifugation was performed with RPE buffer (500 µL) to wash the spin column
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membrane (> 8000 x g). The RNeasy spin column was placed in a new 1.5 mL
collection tube and centrifuged for 1 minute at > 8,000 x g to elute miRNA.
Reverse transcription (RT)
A master mix was created using the guidelines provided in the miScript PCR
System Handbook (Qiagen) (Table 2). The master mix was placed on ice until the
RNA reaction was prepared. The RNA template was prepared as follows: For
each 20 μL RT reaction, master mix was combined with total RNA in the ratio of
1 μL master mix: up to 1 μg total RNA (10pg to 1μg per reaction). MiScript RT
buffer (4 μL) was combined with a pre-designed PTEN primer from Qiagen
(UUCAAGUAAUCCAGGAUAGGCU) and RT master mix; incubated for 60
minutes at 37⁰C then incubated for 5 minutes at 95⁰C to inactivate miScript
Reverse Transcriptase mix. Tubes were stored at -20⁰C if not proceeding directly
to PCR amplification of cDNA.
Real Time-PCR Amplification
A reaction volume of 20 μL was pipetted into a 48-well plate using the following:
Volume/reaction: 10 μL QuantiTect SYBR Green PCR Master Mix (Qiagen), 1
μL Product from RT reaction (cDNA), 2μL 10x miScript Universal
Primer(Qiagen), 2 μL 10x HS_miR-26a-1_1 miScript Primer Assay(Qiagen), 5 μL
of Nuclease-free water (Table 3). Twenty microliters of each sample was placed
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into the wells of a 48-well plate. The plate was centrifuged briefly to mix the
reagents thoroughly. The tubes were held at 95°C for 15 minutes, and then the
following thermal cycling conditions used were: 15 seconds at 94°C to denature,
30 seconds at 55°C to anneal 30 seconds at 70°C for extension (Figure 3). There
were 40 cycles run.
Results
The results for the amplification of miR-26a are shown in Figure 4. Each sample
well tested showed positive amplification for miR-26a compared to the negative
control. This data confirms the presence of the target miRNA within the LN229
glioma cell line.
Discussion
The LN229 cell line was found to contain the miRNA in question, miR-26a. This
result was expected as the LN229 glioma cell line had previously been reported to
contain the microRNA miR26a (Huse et al. 2008). Given these results it could be
predicted that knockdown of miR26a should have an effect on the cellular level
of PTEN protein and the viability of the LN229 glioma cell line.
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Chapter 4
MicroRNA Inhibition
Background
Studies using LN229 GBM cell lines indicate PTEN is “silenced” in a posttranslational mechanism by miR-26a miRNA (Nicoloso and Calin 2008).
Silencing of miR-26a was accomplished via transfection of a miScript miRNA
inhibitor, Anti-has-miR-26a-1 oligonucleotide (Qiagen). Anti-has-miR-26a-1 is a
modified antisense single–stranded oligonucleotide (Qiagen). It is designed to be
complementary to the miR-26a miRNA and specifically inhibits its expression by
binding to miR-26a. Binding of Anti-has-miR-26a-1 oligonucleotide to miR-26a
prevents the miRNA from binding to the PTEN transcript. Transfection was
completed using the Neon transfection system (Invitrogen) using electroporation.
Electroporation is a method used to increase the electrical conductivity and
permeability of the cell plasma membrane, by an externally applied electrical field.
This method is used to introduce new or foreign substances into a cell, such as
anti-miR26a oligonucleotide. The viability of the LN229 cells was determined by
quantitation of the amount of ATP. The luminescence signal generated correlates
with the amount of ATP present, which is directly proportional to the number of
live cells in culture. The smaller the luminescent signal the fewer the number of
live cells present. Western blot was employed to detect increased presence of
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PTEN protein. Knocking down/silencing miR-26a should allow PTEN mRNA
to be translated and potentially increase protein expression.

Materials and Methods
Transfection
Twenty wells of a 96-well plate were used to create and incubate the transfected
cell suspensions (Table 4). Four different miR26a inhibitor concentrations were
used to treat each cell suspension. Untreated cells were electroporated with buffer
only. Inhibitor treated cells were electroporated with the following concentrations
of inhibitor: 50 µM (1.5 µL distilled water, 0.50 µL anti-has-miR-26a-1); 75 µM
(1.25 µL distilled water, 0.75 µL anti-has-miR-26a-1); 100 µM (1.0 µL distilled
water, 1.0 µL anti-has-miR-26a-1); and 200 µM (2.0 µL anti-has-miR-26a-1). The
original stock concentration of the anti-has-miR-26a-1 was 100 nmol. LN229
cells were diluted to 5x103 cells per well in 56 µL of resuspension buffer R
(Invitrogen). Anti-has-miR-26a-1 miScript miRNA inhibitor (Qiagen) treatment
was accomplished by electroporation using the Neon Transfection system
(Invitrogen). Ten microliters of cell suspension including anti-has-miR26a-1miScript miRNA was placed in the Neon pipette station with 3 mL of electrolytic
buffer E (Invitrogen). The LN229 cells were treated with the following
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parameters; Pulse voltage 1050 v, and 40 ms width. This should provide a
transfection efficiency of 73% and a cell viability of 80% as previously
determined by Invitrogen (Table 5). The cell suspension post-pulse was placed
into complete media and incubated at 37°C for a 24 hour period.
CellTiter-Glo Luminescent Assay
After 24 hours of incubation the plate was equilibrated to room temperature for
30 minutes. CellTiter-Glo reagents were added to each well in an amount equal to
the cell culture media (100 µL was used). Contents were mixed for 2 minutes, the
plate was then incubated at room temperature for 10 minutes to stabilize
luminescent signal (Figure 5). Luminescence was recorded at an integration time
of 1 second per well on the Turner Biosystems Modulus microplate luminometer.
Luminescence was measured in relative light units, which correlate with the
number of active cells within the sample.
Statistics
Statistical analysis of data was performed using IBM SPSS Statistics 19 and
Microsoft Excel. A one way ANOVA with Tukey post hoc test was performed
on the luminescence data to determine if there was a significant difference
between the luminescence amounts in the five treatment groups: untreated, 50
µM, 75 µM, 100 µM and 200 µM.
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Western Blot
LN229 cells were plated at a density of 5 x 104 cells/well in a 24-well plate. Ten
microliters of LN229 cells were transfected with anti-has-miR26a-1 at a
concentration of 100 µM with resuspension buffer R (Invitrogen) using the Neon
Transfection system (Invitrogen) as previously described. The cells were then
harvested 24 hours later by direct application of sample lysis buffer to each well.
The lysed cells were used to create a whole cell lysate. Lysis buffer contained 20
mM HEPES and 1% SDS at a pH of 7.3. Sample lysis buffer was placed in
boiling water to warm. One hundred to 150 μL of sample lysis buffer was
administered to each of the 24 wells to lyse the cells. The lysate was pipetted to
mix, collected and pooled in a 15 mL tube, resulting in 4mL total volume. The
LN229 lysate was determined to contain 0.457 ng/µL of protein (Figure 6). The
lysate sample was combined with Laemmli sample buffer and pipetted into a BioRad SDS-Page pre cast gel in 10 µL and 50 µL amounts. The gel was run in 1x
tris/Glycine/SDS running buffer at constant voltage (39 v) for 55 minutes. The
gel was then placed on a nitrocellulose sheet in a transfer cassette (BIO-RAD).
The transfer cassette was placed in western transfer solution (Tris 48 mM,
Glycine 39 mM, SDS 0.04%, 200 mL methanol and 800 mL dH20) at constant
amperage 0.10 A, 39 v and 4 w for 10 hours. After the transfer the nitrocellulose
paper was placed in a 3% nonfat milk blocking buffer for 30 min. The primary
antibody, mouse monoclonal anti-PTEN was applied in a 1:200 dilution and
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incubated for 11 hours. The secondary antibody, goat anti-mouse labeled with
horseradish peroxidase (Thermo scientific), was applied in a 1:1000 dilution for 1
hour. Between the primary and secondary antibody applications the membrane
was washed 3 times for 15 min each in TBST (Table 1). Following final antibody
incubation the membrane was washed 3 more time in TBST prior to
visualization.
Visualization
Protein was visualized using SuperSignal ELISA Pico Chemiluminescent
Substrate. A 1:1 ratio (undiluted) of the substrate was applied to the nitrocellulose
paper. The proteins were imaged using Kodak 1D (Figure 7).
Results
A range of anti-miR26a concentrations were tested; 50, 75, 100 and 200 μM to
determine which concentration had the greatest effect. Each treatment amount of
anti-miR26a had a significant effect (P=0.0004) compared to untreated cells
(Figure 8). The anti-miR26a treatment was consistent in decreasing the LN229
cell line viability through all concentrations, over a 24 hour period. The
electroporation alone did not have a significant effect on cell viability; all
untreated cells were electroporated in subsequent experiments. The western blot
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showed a greater amount of PTEN protein in the anti-miR26a treated LN229
cells, determined by visual inspection (Figure 7).
Discussion
It is clear the inhibition of miR-26a reduced the LN229 cell viability and PTEN
protein levels. Tumor suppressor genes are subject to numerous regulatory
mechanisms including epigenetic effects and posttranslational modifications that
ultimately govern protein levels, activity, binding partners and function (Salmena
et al. 2008). It was demonstrated in studying three human glioblastoma samples
that miR-26a directly targets PTEN and enhances the AKT pathway; transfecting
miR-26a into a murine model showed that over expression enhances
gliomagenesis (Turner et al. 2010). In this study it was demonstrated that
inhibition of miR26a in a cell line that is expressing it, was successful in
decreasing the cells viability. The decrease in cell viability could be due to an
increased amount of PTEN protein. The western blot showed an increase in the
amount of PTEN protein within the LN229 cells treated with anti-miR26a
(Figure 7). The quantification of the increase in PTEN protein amount was based
upon visual inspection. It can be inferred that the increase of PTEN protein
resulted in the decrease in cell viability, possibly due to a reduction in active AKT,
but further research would need to be completed to confirm this.
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Chapter 5
Combination Temozolomide and miR-26a inhibitor Treatment
Background
If the demonstrated inhibition of miR-26a was successful in restoring functional
PTEN protein it is likely to make the LN229 cells more sensitive to
chemotherapy treatment with TMZ. A combination treatment with the anti-miR26a inhibitor and 400 uM (the EC50 dose of TMZ) (Moroz et al. 2011) was tested.
Materials and Methods
Transfection
Thirty wells of a 96 well plate were used to incubate anti-has-miR-26a-1 and
TMZ treated LN229 cells at a density of 5x103 cells/well in 56 µL of
resuspension buffer R (Invitrogen). Cell suspension (100 µL per well) was placed
in a 96 well plate as described in Table 6. Anti-has-miR-26a-1 concentrations
used were as follows: 75 µM (1.25 µL distilled water, 0.75 µL anti-has-miR-26a-1);
100 µM (1.0 µL distilled water, 1.0 µL anti-has-miR26a-1); and 200 µM (2.0 µL
anti-has-miR26a-1. The 50 µM treatment was not used in combination treatment
due to inconsistent results. Transfection of anti-has-miR26a was accomplished by
electroporation using the Neon Transfection System (Invitrogen). Ten microliters
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of cell suspension (cells and resuspension buffer R), including anti-has-miR26a-1,
was placed in the Neon pipette station in 3 mL of electrolytic buffer E
(Invitrogen). The following treatment parameters were applied; Pulse voltage
1050 v, and 40 ms width. This should provide a transfection efficiency of 73%
and a cell viability of 80% as previously determined by Invitrogen (Table 5). The
cell suspension post-pulse was placed into complete media containing EC50
dosage of TMZ (400uM) (Moroz et al. 2011). The cells were incubated at 37°C
for a 24 hour period.
CellTiter-Glo Luminescent Assay
After 24 hours of incubation the plate was equilibrated to room temperature for
30 minutes. CellTiter-Glo reagents were added to each well in an amount equal to
the cell culture media of each well (100 µL was used). Contents were mixed for 2
minutes, the plate was then incubated at room temperature for 10 minutes to
stabilize luminescent signal. Luminescence was recorded at an integration time of
1 second per well on the Turner Biosystems Modulus microplate luminometer.
This test should show if indeed the presence of functional PTEN within the cell
is beneficial for increasing a chemotherapy agent’s effect and decreasing the
LN229 cells viability. Three different trials were completed; each was conducted
as a separate experiment to ensure results were consistent.
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Statistics
Statistical analysis of data was performed using IBM SPSS Statistics 19 and
Microsoft Excel. A one way ANOVA with Tukey post hoc test was performed
on the luminescence data to determine if there was a significant difference
between the luminescence amounts in the three treatment groups: untreated,
inhibitor only treated, TMZ only and combination (TMZ and inhibitor)
treatment.
Results
Compared to anti-has-miR26a-1 treatment only the combination treatment of
anti-has-miR26a-1 and TMZ significantly decreased cell viability over a 24 hour
period in trial 1 (Figure 9). Trial 2 (Figure 10) shows the combination of Antihas-miR26a miRNA and TMZ treatment had a greater effect on decreasing cell
viability than the inhibitor only.
Discussion
Statistical analysis of data was performed to determine significant between
miR26a inhibitor treated LN229 cells and untreated LN229 cells. A one-way
ANOVA with Tukey post-hoc test confirmed a significant difference (P=0.0001)
between the treatment groups (inhibitor, TMZ, and combination). The decrease
in cell viability is thought to be due to an increase in functional PTEN protein,
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this was supported by the western blot results (Figure 7). The combination of
TMZ and miR-26a inhibitor had a greater effect on LN229 cell viability then
either inhibitor or TMZ only in trial 3 (Figure 11). The inhibitor only treatment
reduced cell viability and appeared to cause an increase in PTEN protein. Even
with the PTEN protein increase the inhibitor only treatment was not as effective
at reducing cell viability as the TMZ only or combination treatments in trials 2
and 3. The inhibitor only might have been less effective because of residual
activated AKT present in the cell. The results of the combination treatment
showed further reduction in cell viability which appeared to be greater than either
the anti-miR26a or TMZ treatments alone. These results indicate that miR-26a is
a viable target to increase the efficacy of TMZ treatment. The electroporation did
not have a significant effect on the cell growth.
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SYNOPSIS AND CONCLUSIONS

This study showed the inhibition of miR-26a when combined with TMZ
treatment results in an increased TMZ response and a decrease in cell viability.
This suggests that the presence of the anti-miR26a oligo binds miR-26a and
inhibits its ability to decrease the translation of PTEN mRNA into protein.
Down regulation of miR-26a could be confirmed by real time PCR, but was not
in this study. The up regulation of PTEN protein was visually confirmed by the
western blot of the anti-has-miR-26a miRNA treated cells. The LN229 cells were
successfully transfected using the Neon transfection system (Invitrogen) through
electroporation. The electroporation did not have a significant effect on the
LN229 cells viability. Other means of PTEN detection could be used to verify up
regulation. PCR for the mRNA PTEN transcript could be used to compare pre
and post transfection levels. Immunocytochemistry could be used to stain the
cells directly for PTEN protein presence. MiR-26a has a complex role in cancer.
It has been demonstrated in hepatocellular carcinoma miR26a has reduced
expression compared to the high levels of normal expression in diverse tissue
(Kota et al. 2009). A balance is needed for miRNAs to help regulate normal
cellular proliferation. The literature has support for both sides of the tumor
suppressor/oncogenic argument, indicating the need for a clearer picture of
miRNAs involvement in tumorgenesis. Clearly inhibition of miR26a has an effect
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on the viability of LN229 cells. This is a beneficial finding because inhibition of
miR-26a allows the current standard of GBM care, TMZ, to work more
effectively. All results indicate miR-26a miRNA is a plausible target in GBM
therapy.
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FUTURE DIRECTIONS

Other studies that could be performed to further this research would be to
compare these results with similar tests performed on PTEN mutated cells, such
as the U87 GBM cell line. Comparing wild-type PTEN cells with mutated PTEN
cells would give a greater indication that miR26a is in fact inhibiting PTEN
protein production. Additionally looking at downstream effects of anti-miR26a
application would be helpful in clarify the miRNAs function. Targets such at
AKT activity after treatment with anti-miR26a might help create a clearer picture
of the effect miR26a has on the cell cycle. Exiqon has been developing a protocol
to sample amounts of miRNA within serum samples from patients. This protocol
has the potential to be used as a prognostic factor for the severity of one’s tumor;
currently the protocol only involves colo-rectal cancer.

This is a potential

stepping stone for a non-invasive test to determine a patient’s tumor severity,
possible even how a tumor would react to chemotherapy treatment with TMZ.
For example if a patient had a blood sample taken and miR26a was found in a
substantial amount it could be inferred that the tumor might be less sensitive to
TMZ than if there was no miR26a present in the sample. The fact that miRNA
overexpression in cancer has a pathogenic effect provides the rationale for using
miRNAs as potential therapeutic targets in cancer. A robust increase in miR-21
expression was found in six commonly used model cell lines derived from human
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glioblastoma, this represents only initial studies that should be followed by large
trials in patients with brain cancers to support the biomarker roles for miRNAs
( Nicoloso & Calin 2008).
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APPENDIX A

Figures and Tables

1

Figure 1.Biogenesis of microRNA. Begins in the nucleus with Drosha and
Pasha. Once in the cytoplasm Dicer cleaves the double stranded miRNA
complex to create a mature miRNA. Mature miRNA can then assemble miRISC.
If imperfect complementarity translation is repressed, perfect complementarity is
cleaved and degraded (Esquela-Kerscher and Slack 2006).

1

Figure 2. Western Blot for PTEN. The clear bands imaged confirm PTEN
protein within LN229 lysate. The lysate amount from left to right is 15 µL, 50
µL, 15 µL and 50 µL.

1

Figure 3. RT-PCR Cycling conditions for RT- PCR using StepOne Real-Time
PCR System, 40 cycles were completed.

1

Figure 4. Amplification of miR-26a using RT-PCR. Primer RNA for miR26a (UUCAAGUAAUCCAAGGAUAGGCU) was combined with RT buffer
and RT master mix to create cDNA for miR-26a. The cDNA was combined with
SYBR Green PCR master mix and HS_miR-26a1_1 primer to produce the above
amplification plot. The change in Rn shows an increase in miR-26a as cycles
continue; this confirms the presence of miR-26a in the LN229 cells.

1

Figure 5. Cell-Titer Glo Reaction. Cell-Titer Glo measures cell viability by
presence of ATP, and is directly proportional to the amount of active cells
present in the suspension. The reaction shows how luminescence is created to
provide quantitation of ATP present.

1

Figure 6. BCA Protein Concentration. Standard graph of
protein concentrations used to determine amount of protein
in LN 229 lysate sample (0.457 µg/ µL)

1

50 µL
untreated

50 µL
treated

Figure 7. Western Blot of PTEN: post transfection. Visually there was an
increase in the amount of PTEN in the treated cells compared to the untreated
cells.
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Figure 8. Cell viability after treatment with anti-miR-26a oligo. There is a
significant decrease in cell viability in the LN229 cells treated with all anti-miR26a oligo concentrations compared to the untreated LN229 cells at all inhibitor
concentrations (P=0.0004). There was no significant difference between the
concentration amounts.
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Figure 9. Silencing of miR-26a 24 hours post transfection trial 1. Untreated
cells had the greatest luminecense indicating more viabile cells were present in
that treatment. Inhibitor only had less luminecense then TMZ only. The
combination treatment had the least amount of luminecense indicating the least
amount of active cells. The bars with the same letters do not differ, the bars with
differing letters are significantly different (P=0.00001).

1

Figure 10. LN229 inhibition of miR-26a combined with TMZ trial 2. It is
clear the combination of miR26a inhibitor with TMZ had a greater effect on
LN229 cell viability compared to inhibitor alone, the different letters indicate
significant difference between treatments (P=0.0001). A one way ANOVA was
performed with Tukey post-hoc (P=0.0001), indicating there is a significant
difference between the treatment groups (untreated, inhibitor only, and
combination. The bars with the same letters do not differ.
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Figure 11. Cell viability of LN229 cell line after miR-26a inhibition plus
TMZ trial 3. Once again the combination treatment (miR26a inhibitor and
TMZ) had a significant effect on LN229 cell viability after 24 hours of application
compared to the TMZ and anti-miR26a only treatments (P<0.001). Differing
letters indicate the significant difference between treatments (untreated, inhibitor
only, TMZ only, and inhibitor and TMZ).
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Table 1. TBST Solution. Western transfer solution components.
Component

Concentration
/ Amount
48 mM (5.8g)
39 mM (2.9g)
0.04% (0.37g)
200 mL
800 mL

Tris
Glycine
SDS
Methanol
Distilled H2O

Table 2. Reaction components for reverse transcription. Reverse
transcription was performed on total extracted RNA from LN229 cells. The
resulting cDNA was used in PCR for amplification of miR-26a, confirming
presence in the cell line.
Component
miScript RT Buffer,
5x
RNase-free Water
miScript
Reverse
Transcriptase mix
Template RNA
TOTAL

1

Volume
1 reaction (µ L)
4
14
1
1 µg
20

Table 3. Reaction components for PCR Assay. PCR was performed in the
StepOne Real-Time PCR cycler. Amplification of miR26a confirmed its presence
in the LN229 cell line.

Component
2x QuantiTect SYBR Green
PCR Master Mix
10x miScript Universal
Primer
10x miScript Hs_miR-26a1_1 Primer Assay
RNase-free Water
Template cDNA
TOTAL

1

Volume
1 reaction (µL)
10
2
2
5
1
20

Table 4. Well Plate Template. Schmatic of 96-well plate set up for cell
incubation after Neon Transfection of miR-26a inhibitor. MiR-26a inhibitor
wells contained 10 uL of cell suspension and 90 uL of complete media. Untreated
cells were electroporated and placed into complete media; they contained no
inhibitor.

AntimiR-26a

AntimiR-26a

LN229
Cells

LN229
Cells

A

0µM

0 um

Untreated Untreated

B

50 µ M

50 µ M

Untreated Untreated

C

75 µ M

75 µ M

Untreated Untreated

D

100 µ M

100 µ M Untreated Untreated

E

200 µ M

200 µ M Untreated Untreated

1

Electroporation parameters
Pulse
voltage
(v)
1,050

Pulse
width
(ms)
40

Pulse
number
1

Cell
density
(cells/ml)
5 x 106

Transfection
efficiency

Viability

73%

80%

Tip type
10 μl

Table 5. Electroporation parameters. Parameters for electroporation of glioma
cell lines as previously determined by Invitrogen, for successful transfection.
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miR26a miR26a
Inhibitor Inhibitor

miR26a miR26a
Inhibitor Inhibitor
&TMZ
&TMZ

A

0µM

0 um

Untreated Untreated

0µM

0µM

TMZ
only

B

75 µ M

75 µ M

Untreated Untreated

75 µ M

75 µ M

TMZ
only

C

100 µ M

100 µ M

Untreated Untreated

100 µ M

100 µ M

TMZ
only

D

200 µ M

200 µ M

Untreated Untreated

200 µ M

TMZ
only

Table 6. Combination treatment plate setup. The following 96 well plate
schematic illustrates the setup for transfection with miR-26a inhibitor plus TMZ
treatment. The plate was read using the Cell-Titer Glo Cell Viability assay 24
hours after treatment.
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